Avanos CFO awarded new options and TRSUs

AVANOS MEDICAL, INC. reported that its SVP and Chief Financial Officer, Scott Michael Galovan, received new equity awards as part of his compensation.

Rhea-AI Filing Summary

AVANOS MEDICAL, INC. reported that its SVP and Chief Financial Officer, Scott Michael Galovan, received new equity awards as part of his compensation. He was granted an employee stock option for 70,115 shares of Common Stock at an exercise price of $13.69 per share, expiring on March 13, 2036, bringing his option holdings to 96,697 options after the grant.

He also received 29,481 time-based restricted share units (TRSUs), increasing his direct Common Stock holdings to 139,824 shares after the award. According to the footnotes, one TRSU equals one share of Common Stock, with vesting in tranches on March 13, 2027, March 13, 2028, and March 13, 2029.

Insider Trade Summary

Grant/Award: 99,596 shares

Grant/Award 2 txns

Insider Galovan Scott Michael

Role SVP, Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	70,115	$0.00	$0.00
Grant/Award	Common Stock	29,481	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 96,697 contracts (Direct); Common Stock — 139,824 shares (Direct)

Footnotes (2)

1. F1. Represents time-based restricted share units (TRSUs) awarded pursuant to the Issuer's 2021 Long Term Incentive Plan, as amended. The award will vest 1/3 on March 13, 2027, 1/3 on March 13, 2028 and 1/3 on March 13, 2029. Each TRSU is the economic equivalent of one share of Common Stock.
2. F2. The award will vest 30% on March 13, 2027, 30% on March 13, 2028 and 40% on March 13, 2029.

Key Figures

Option grant size: 70,115 options Option exercise price: $13.69 per share Option expiration: March 13, 2036 +4 more

7 metrics

Option grant size 70,115 options Employee stock option granted on March 13, 2026

Option exercise price $13.69 per share Exercise price for 70,115 options

Option expiration March 13, 2036 Expiration date of new option grant

Options after grant 96,697 options Total options held following transaction

TRSU award size 29,481 TRSUs Time-based restricted share units granted

Common shares after award 139,824 shares Direct Common Stock holdings following TRSU grant

TRSU vesting splits 1/3-1/3-1/3 and 30%-30%-40% Vesting pattern across 2027, 2028, 2029

Key Terms

time-based restricted share units (TRSUs), 2021 Long Term Incentive Plan, economic equivalent of one share of Common Stock, Grant, award, or other acquisition, +1 more

5 terms

time-based restricted share units (TRSUs) financial

"Represents time-based restricted share units (TRSUs) awarded pursuant to the Issuer's 2021 Long Term Incentive Plan"

2021 Long Term Incentive Plan financial

"TRSUs awarded pursuant to the Issuer's 2021 Long Term Incentive Plan, as amended"

economic equivalent of one share of Common Stock financial

"Each TRSU is the economic equivalent of one share of Common Stock"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Employee Stock Option (right to buy) financial

"security_title: Employee Stock Option (right to buy)"

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/01/2026 - 11:46 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Galovan Scott Michael

(Last) (First) (Middle)

5405 WINDWARD PARKWAY

SUITE 100

(Street)

ALPHARETTA GEORGIA 30004

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AVANOS MEDICAL, INC. [ AVNS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
03/17/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/13/2026		A		29,481(1)	A	$0	139,824	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$13.69	03/13/2026		A		70,115		(2)	03/13/2036	Common Stock	70,115	$0	96,697	D

Explanation of Responses:

1. Represents time-based restricted share units (TRSUs) awarded pursuant to the Issuer's 2021 Long Term Incentive Plan, as amended. The award will vest 1/3 on March 13, 2027, 1/3 on March 13, 2028 and 1/3 on March 13, 2029. Each TRSU is the economic equivalent of one share of Common Stock.

2. The award will vest 30% on March 13, 2027, 30% on March 13, 2028 and 40% on March 13, 2029.

Remarks:

This Form 4/A is being filed to correct an error in the calculation of the number of stock options issued to the Reporting Person on March 13, 2026 pursuant to the Issuer's 2021 Long-Term Incentive Plan, as amended.

	/s/ John Hurley, as attorney-in-fact for Scott M. Galovan	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)